A highly anticipated cholesterol drug from Novartis failed to reduce the risk of severe cardiovascular outcomes in a Phase 3 study

The Phase 3 study found a drug didn't reduce the risk of cardiovascular events like heart attacks and strokes.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。